Drug Trial Radar · NCT05080959
A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy
Last checked: Nov 19, 2026Latest source record: Jul 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jul 28, 2021
Primary completion
Dec 31, 2021
Study completion Jun 10, 2022
Sponsor
- Lead sponsor
- Cali Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b, randomized, double blind, placebo and active controlled study with an Ascending Dose Stage and an optional Dose Expansion Stage in subjects undergoing open inguinal herniorrhaphy with mesh.
Conditions
- Inguinal Herniorrhaphy
Interventions
CPL-01Drug
Subjects will receive a single dose
Naropin 150 MG Per 20 ML InjectionDrug
Subjects will receive a single dose
PlaceboDrug
Subjects will receive a single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC of the NRS-A for pain (Primary Endpoint)Time frame: 0 - 72 hours
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Shoals Medical Trials, Inc
Sheffield, Alabama
Arizona Research Center
Phoenix, Arizona
Anaheim Clinical Trials
Anaheim, California
First Surgical Hospital
Bellaire, Texas
Jean Brown Research
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.